Drugs / dalotuzumab
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT01431547 | Feb 2012 → Sep 2013 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01243762 | Nov 2010 → Dec 2012 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01220570 | Sep 2010 → Dec 2012 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00925015 | Jun 2009 → Jul 2010 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00729742 | Feb 2009 → Jun 2010 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00759785 | Sep 2008 → Feb 2010 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00694356 | Aug 2008 → Mar 2009 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00730379 | Jul 2008 → Nov 2010 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00635778 | Aug 2006 → Nov 2008 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00701103 | Jan 2006 → Dec 2009 | plasma cell myeloma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT00869752 | Dec 2009 → Mar 2012 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00769483 | Nov 2008 → Sep 2020 | pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Completed | Missed primary |
| Phase 28 trials · 4 missed | ||||||
| Phase 2 | NCT01609231 | Jul 2012 → Dec 2014 | rectal neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01605396 | Jul 2012 → Feb 2014 | breast neoplasm | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT01234857 | Sep 2010 → Oct 2013 | breast cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00799240 | Jun 2009 → Feb 2011 | non-small cell lung carcinoma | University of Kansas | Completed | No outcome recorded |
| Phase 2 | NCT00654420 | Mar 2008 → Nov 2009 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00610129 | Jan 2008 → Jan 2010 | neuroendocrine neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00614393 | Dec 2007 → Jun 2010 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00951444 | — | lung cancer | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00903006 Comparator | Nov 2009 → May 2013 | breast cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01175291 Comparator | Sep 2010 → Jul 2012 | colorectal cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dalotuzumab | “Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.” PMID 26793618 ↗ Jan 201617“NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.” PMID 24518092 ↗ Mar 2014 |
| Known as | MK-0646 | “Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks” NCT01220570 ↗9“Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets IGF-1R.” PMID 26793618 ↗ Jan 2016 “ridaforolimus (MK8669) + dalotuzumab (MK0646)” NCT00730379 ↗ “Dalotuzumab (MK0646)” NCT00729742 ↗ “dalotuzumab (MK0646)” NCT00759785 ↗ |
| Action | Inhibit | “By attaching to the target, it may stop the cancer cells from further growth and dividing.” NCT00610129 ↗ |
| Modality | Monoclonal antibody | “MK-0646 is a monoclonal antibody.” NCT00610129 ↗ |
| Route | Intravenous | “for IV infusion” NCT00610129 ↗ |
| Target | IGF1R | “Dalotuzumab is a humanized monoclonal antibody (mAb) that targets the Insulin-like Growth Factor Receptor (IGF-1R).” NCT00654420 ↗ |